No studies have shown a correlation between NHE1 disruption and human disease, but it is clear that NHE1 is an important pharmacological target in some pathophysiological situations as ischemic heart disease and human breast cancer (Malo and Fliegel, 2006). This evidence concerns the gene SLC9A1 and breast carcinoma.